Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have received an average rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.43.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Thursday. ValuEngine lowered shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research note on Tuesday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a research note on Friday, June 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th.
In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $10.51, for a total transaction of $734,165.54. Following the sale, the insider now directly owns 2,490,952 shares of the company’s stock, valued at $26,179,905.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director George Harrison Talbot sold 325 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $100.56, for a total transaction of $32,682.00. Following the completion of the sale, the director now directly owns 3,854 shares in the company, valued at $387,558.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 242,708 shares of company stock worth $2,646,784.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Almanack Investment Partners LLC. acquired a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $1,870,000. Renaissance Technologies LLC acquired a new stake in shares of Nabriva Therapeutics AG during the fourth quarter worth approximately $103,000. Wellington Management Group LLP raised its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth approximately $2,074,000. Institutional investors own 56.65% of the company’s stock.
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 9.79 on Tuesday. The firm’s market cap is $26.64 million. The firm has a 50-day moving average of $10.42 and a 200 day moving average of $10.33. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. On average, equities research analysts forecast that Nabriva Therapeutics AG will post ($2.43) earnings per share for the current year.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.